3 min read

UBC Joins New Industry Coalition DTRA to Accelerate Decentralized Research

UBC is proud to be a founding member of the DTRA and accelerate the broad adoption of patient-focused, decentralized clinical trials and research.
UBC is proud to be a founding member and accelerate patient-focused research.

In the wake of the COVID-19 health crisis, the entire biopharmaceutical industry is coming together to ensure the advancement of patient access to critical research studies and novel treatments. Together, we are working to remove barriers to make trial and research access safe and convenient, by accelerating the adoption of technology-enabled remote data collection practices.

“We are honored to join the DTRA at such a pivotal moment for the entire healthcare system. The pandemic has presented myriad challenges for pharmaceutical manufacturers, research organizations, and regulators” said Aaron Berger, Executive Director, Late Stage Operations & RWE, a leading voice in evidence generation strategies. “To meet these challenges, a robust array of decentralized trial solutions are needed, including digital patient engagement, technology-enabled data acquisition, and in-home nursing. We are introducing one or more of these strategies into study design discussions with our sponsor partners.”

Since March, UBC’s comprehensive suite of solutions has helped many clients mitigate the risks that surround bringing treatments to market in today’s challenging environment.

“Through the utilization of direct-to-patient and digital strategies, we have been able to modernize and accelerate the way we gather critical data and insights needed for regulatory decisions and beyond. Our wide array of decentralized study capabilities to collect critical evidence beyond the walls of the traditional study setting, remotely or in the patient’s home. These are the types of experiences we are keen to share with fellow leaders and industry stakeholders as part of our role in the DTRA and the future of clinical development.” Berger concludes.

About DTRA:

The Decentralized Trials & Research Alliance (DTRA) was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research. It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods.

For more information regarding UBC’s virtual & decentralized research solutions, head here.

Other Recent Posts

Press
5 min read

UBC and Thread Expand SitePlus Offering and Active Studies with BioPharma Sponsors to Optimize Evidence Generation

This augments the central site model with additional research services and tech to widen recruitment and improves site and patient experience.
Press
3 min read

UBC Appoints Anthony Luttenberger Chief Commercial Officer

Biopharma services industry veteran brings decades of experience spanning late-stage, clinical trials, & post-approval commercial support.
Press
1 min read

UBC Listed as a Citeline Awards Finalist for Excellence in RWE

UBC is once again a finalist for the Citeline Awards, with our 2024 nomination coming in the Excellence in RWE category.
UBC logo white

Thank You for Connecting with UBC

Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.

What You Can Expect Next

Lorem ipsum dolor sit amet consectetur. Cras aliquam erat eget magna sollicitudin.

UBC logo white

Get Ready to Change Your Business

Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.

Service Request

Bekki Bracken Brown Headshot

Bekki Bracken Brown

President & Chief Executive Officer

Bekki Bracken Brown serves as the President and CEO of UBC, guiding the company’s mission and values, including the improvement of access for patients to receive better outcomes. She oversees all aspects of UBC, such as operations, business growth strategy, sales and marketing, and acquisition support.

With over 20 years of industry experience, Ms. Brown brings knowledge from a successful career in senior management from her tenure at Quintiles, INC Research, and, most recently, with Syneos Health. She’s been a member of the North Carolina BIO Board of Directors since 2019. She is also a member of the Healthcare Businesswomen’s Association — Southeast Chapter and CHIEF, an organization that supports women executive leaders. Ms. Brown earned her bachelor’s degree at Duke University.